Table 4.

Median change of circulating biomarkers.

			Baseline	Six weeks	Change
Variable	Treat.	N Obs	Median IQR	Median IQR	Median IQR	Contrast1	P
Fibrinogen	P	25	312.0 (273.0 to 340.0)	333.5 (276.0 to 354.0)	4.5 (-19.0 to 24.0)	T vs. R	0.02
mg/dL	R	50	301.0 (254.0 to 334.0)	260.0 (230.0 to 288.0)	-29.5 (-61.0 to -5.0)	T + R vs. P	0.01
	T	50	286.0 (247.0 to 319.0)	285.0 (243.0 to 312.0)	-2.0 (-20.0 to 12.0)
Antithrombin	P	25	102.0 (98.0 to 109.0)	99.0 (93.0 to 104.0)	-1.0 (-5.0 to 4.0)	T vs. R	0.75
%	R	50	103.0 (98.0 to 108.0)	94.0 (90.0 to 101.0)	-8.0 (-11.0 to -1.0	T + R vs. P	0.02
	T	50	106.0 (98.0 to 114.0)	100.0 (92.0 to 106.0)	-7.0 (-16.0 to -1.0)
CRP	P	25	0.6 (0.3 to 2.8)	0.8 (0.3 to 3.3)	0.0 (-0.1 to 0.6)	T vs. R	0.12
mg/dL	R	50	1.0 (0.5 to 1.9)	0.6 (0.4 to 1.3)	-0.3 (-0.7 to 0.1)	T + R vs. P	0.21
	T	50	0.7 (0.4 to1.2)	0.8 (0.4 to 1.3)	0.1 (-0.3 to 0.3)
Cholesterol	P	25	199.0 (185.0 to 224.0)	225.5 (197.0 to 244.0)	13.5 (1.0 to 33.0)	T vs. R	0.30
mg/dL	R	50	199.5 (179.0 to 222.0)	192.0 (168.0 to 215.0)	-7.0 (-23.0 to 5.0)	T + R vs. P	<.0001
	T	50	201.5 (180.0 to 220.0)	188.5 (171.0 to 200.0)	-12.0 (-18.0 to 0.0)
CTX ng/mL	P	25	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.3)	0.0 (-0.1 to 0.0)	T vs. R	0.05
	R	50	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	0.0 (0.0 to 0.1)	T + R vs. P	0.58
	T	50	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	0.0 (-0.1 to 0.0)
Osteocalcin	P	25	16.9 (13.4 to20.3)	16.5 (13.1 to 22.5)	-0.5 (-1.9 to 2.2)	T vs. R	0.39
ng/mL	R	50	17.9 (13.8 to 22.5)	16.8 (13.4 to 20.8)	-1.7 (-3.5 to 1.1)	T + R vs. P	0.32
	T	50	16.0 (61.98 to 165.5)	15.3 (12.5 to 20.2)	-0.7 (-2.0 to 1.0)

¹Change adjusted for baseline. CRP, C-reactive protein; CTX, C-telopeptide; IQR, interquartile range; P, placebo; R, raloxifene 60 mg/day; T, tamoxifen 10 mg/week.